Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.
(2014) In Epilepsia 55(1). p.167-174- Abstract
- Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to... (More)
- Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to rapid kindling, a model for recurrent temporal lobe seizures. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4179212
- author
- Nikitidou, Litsa LU ; Torp, Malene ; Fjord-Larsen, Lone ; Kusk, Philip ; Wahlberg, Lars U and Kokaia, Merab LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Epilepsia
- volume
- 55
- issue
- 1
- pages
- 167 - 174
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000329893900021
- pmid:24245512
- scopus:84892907722
- pmid:24245512
- ISSN
- 0013-9580
- DOI
- 10.1111/epi.12470
- language
- English
- LU publication?
- yes
- id
- 0eed1f37-f991-4b72-9cef-3d2ad1cb7353 (old id 4179212)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24245512?dopt=Abstract
- date added to LUP
- 2016-04-01 10:55:52
- date last changed
- 2022-02-02 22:19:03
@article{0eed1f37-f991-4b72-9cef-3d2ad1cb7353,
abstract = {{Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to rapid kindling, a model for recurrent temporal lobe seizures.}},
author = {{Nikitidou, Litsa and Torp, Malene and Fjord-Larsen, Lone and Kusk, Philip and Wahlberg, Lars U and Kokaia, Merab}},
issn = {{0013-9580}},
language = {{eng}},
number = {{1}},
pages = {{167--174}},
publisher = {{Wiley-Blackwell}},
series = {{Epilepsia}},
title = {{Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.}},
url = {{http://dx.doi.org/10.1111/epi.12470}},
doi = {{10.1111/epi.12470}},
volume = {{55}},
year = {{2014}},
}